Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study
- PMID: 21044307
- PMCID: PMC2988053
- DOI: 10.1186/1471-2334-10-318
Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study
Abstract
Background: The mortality in patients with persistent low CD4 count despite several years of HAART with sustained viral suppression is poorly documented. We aimed to identify predictors for inadequate CD4 cell recovery and estimate mortality in patients with low CD4 count but otherwise successful HAART.
Method: In a nationwide cohort of HIV patients we identified all individuals who started HAART before 1 January 2005 with CD4 cell count ≤ 200 cells/μL and experienced three years with sustained viral suppression. Patients were categorized according to CD4 cell count after the three years suppressed period (≤ 200 cells/μL; immunological non-responders (INRs), >200 cells/μL; immunological responders (IRs)). We used logistic regression and Kaplan-Meier analysis to estimated risk factors and mortality for INRs compared to IRs.
Results: We identified 55 INRs and 236 IRs. In adjusted analysis age > 40 years and > one year from first CD4 cell count ≤ 200 cells/μL to start of the virologically suppressed period were associated with increased risk of INR. INRs had substantially higher mortality compared to IRs. The excess mortality was mainly seen in the INR group with > one year of immunological suppression prior to viral suppression and injection drug users (IDUs).
Conclusion: Age and prolonged periods of immune deficiency prior to successful HAART are risk factors for incomplete CD4 cell recovery. INRs have substantially increased long-term mortality mainly associated with prolonged immunological suppression prior to viral suppression and IDU.
Figures



Similar articles
-
The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China.BMC Immunol. 2019 Aug 28;20(1):31. doi: 10.1186/s12865-019-0311-2. BMC Immunol. 2019. PMID: 31455209 Free PMC article.
-
The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.PLoS One. 2016 Feb 22;11(2):e0148915. doi: 10.1371/journal.pone.0148915. eCollection 2016. PLoS One. 2016. PMID: 26900702 Free PMC article.
-
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.Clin Infect Dis. 2014 May;58(9):1312-21. doi: 10.1093/cid/ciu038. Epub 2014 Jan 22. Clin Infect Dis. 2014. PMID: 24457342 Free PMC article.
-
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.Clin Dev Immunol. 2012;2012:670957. doi: 10.1155/2012/670957. Epub 2012 Mar 14. Clin Dev Immunol. 2012. PMID: 22474480 Free PMC article. Review.
-
Failure of CD4+ T-cell Recovery upon Virally-Effective cART: an Enduring Gap in the Understanding of HIV+ Immunological non-Responders.New Microbiol. 2022 Jul;45(3):155-172. New Microbiol. 2022. PMID: 35920870 Review.
Cited by
-
A Summary of the First HIV Microbiome Workshop 2015.AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):935-941. doi: 10.1089/AID.2016.0034. Epub 2016 Jul 14. AIDS Res Hum Retroviruses. 2016. PMID: 27267576 Free PMC article.
-
Harnessing CD8+ T Cells Under HIV Antiretroviral Therapy.Front Immunol. 2019 Feb 26;10:291. doi: 10.3389/fimmu.2019.00291. eCollection 2019. Front Immunol. 2019. PMID: 30863403 Free PMC article. Review.
-
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study.Front Med (Lausanne). 2023 Jun 21;10:1182359. doi: 10.3389/fmed.2023.1182359. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37415770 Free PMC article.
-
Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.PLoS One. 2016 Jun 10;11(6):e0156099. doi: 10.1371/journal.pone.0156099. eCollection 2016. PLoS One. 2016. PMID: 27284683 Free PMC article.
-
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549. J Acquir Immune Defic Syndr. 2015. PMID: 25942459 Free PMC article.
References
-
- Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87–95. - PubMed
-
- Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M. Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163(18):2187–2195. doi: 10.1001/archinte.163.18.2187. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials